Mishari Tariq Alrubaiaan

Background: The era of social media platforms has transformed the dissemination of health information, raising concerns about the quality and accuracy of content. Urticaria, a common skin condition, necessitates reliable information for effective management. Unreliable information on the internet can lead to misconceptions about urticaria, which could contribute to overemphasis on triggers or underrepresentation of guideline-based interventions, delaying effective management approaches. Objective: This study aimed to systematically evaluate urticaria-related content on 2 prominent social media platforms, YouTube and TikTok, using validated tools to assess information reliability and explore the characteristics of videos and their uploaders. Methods: On February 16, 2023, a comprehensive search on YouTube and TikTok was conducted for videos related to urticaria. Two independent dermatologists rated 92 eligible videos using DISCERN, the Global Quality Score (GQS), and the Accuracy in Digital-Health Instrument (ANDI). Statistical analyses, including mean values, SDs, percentages, and chi-square tests, were used to interpret the data. Results: TikTok videos were predominantly uploaded by patients (29/46, 63%), whereas YouTube exhibited a higher engagement of health care professionals (31/46, 67.4%). YouTube videos exhibited higher mean scores for the GQS (2.9, SD 0.7), ANDI (2.3, SD 0.8), and DISCERN (40.2, SD 7.6) compared to TikTok (GQS: mean 2, SD 0.8; ANDI: mean 1.4, SD 1; DISCERN: mean 32.9, SD 7.9). Videos uploaded by professionals on TikTok had significantly higher mean GQS (2.8, SD 0.7), ANDI (2.1, SD 0.8), and DISCERN (40, SD 6.3) scores compared to those uploaded by nonprofessionals ( P =.001). Similarly, videos from professional uploaders on YouTube exhibited significantly higher mean GQS (3, SD 0.6), ANDI (2.6, SD 0.6), and DISCERN (42.2, SD 7.1) scores compared to nonprofessionals ( P =.01 for GQS, P =.001 for ANDI, and P =.003 for DISCERN). Conclusions: Urticaria videos on TikTok showed a significantly higher engagement ratio and less accuracy and quality of health-related information than YouTube videos. These insights can guide content creators, platform administrators, and health care professionals in collaboratively fostering a trustworthy and accurate health information environment on social media.

Background: Nevus of Ota is a pigmentary condition distinguished by blue to gray‐brown macules. In recent years, laser therapy has become the favored treatment method, with the 1064 nm Q‐switched Nd: YAG laser (QSNYL) considered the traditional treatment. 755‐nm Picosecond alexandrite lasers (PSAL) have demonstrated potential as effective alternatives; however, direct comparative research between these two modalities is limited. Objectives: To present an updated comparison of the safety and efficiency of 755‐nm PSAL and QSNYL in the management of nevus of Ota. Methods: A PubMed, ScienceDirect, and Google Scholar search was performed. Studies were eligible for inclusion if they involved patients with nevus of Ota who received treatment with 755‐nm PSAL or QSNYL and provided outcome data. Random‐effects meta‐analyses were performed using the R software. Results: Twenty‐two studies included 2667 individuals with nevus of Ota. Success rates were markedly higher with PSAL (76.10%; 95% CI [33.62–95.24]) than with QSNYL (47.59%; 95% CI [19.48–77.31]). PSAL exhibited higher rates of post‐inflammatory hyperpigmentation (PSAL: 16.74% compared to QSNYL: 8.02%) and hypopigmentation (PSAL: 8.41% vs. QSNYL: 4.48%). The recurrence rate was relatively low for both lasers, with PSAL exhibiting a slightly higher rate (PSAL: 5.32% vs. QSNYL: 2.54%). Conclusion: PSAL may have superior efficacy to QSNYL for pigment clearance in patients with nevus of Ota. However, they are also associated with a higher incidence of adverse events. Since QSNYL is an established, reliable traditional treatment, further research with direct comparison is still required to determine if PSAL is a reliable alternative.

Background: The nevus of Ota is an uncommon pigmentary skin condition that causes bluish-gray pigmentation and is traditionally treated with a Q-switched laser. Emerging evidence suggests that the 755-nanometer picosecond alexandrite laser is a safe and effective therapeutic option. We sought to determine the overall effectiveness and safety profile of the 755-nanometer (nm) picosecond alexandrite laser for managing nevus of Ota. Methods: We reviewed 6 databases for studies that addressed the safety as well as efficacy profile of the 755-nm picosecond alexandrite laser for nevus of Ota. Ten studies, including 558 individuals with nevus of Ota, were included. The main outcomes were the rate of excellent clinical response and reported side effects encompassing erythema as well as post-inflammatory pigmentary alterations, including both hyperpigmentation and hypopigmentation. Review Manager Version 5.4 and Comprehensive Meta-Analysis v3 software were used for data analysis. Results: The pooled excellent clinical response rate for the 755-nm picosecond alexandrite laser was found to be 36.8% (95% confidence interval [24.4–51.2%], P = .642). Post-inflammatory hyperpigmentation and hypopigmentation were each observed in 20.6% and 12.2% of the cases ( P -value < .001), respectively. Post-inflammatory erythema, assessed in 2 studies (n = 23), demonstrated a pooled prevalence of 45.2% (95% confidence interval: 12.9–82.2%). Conclusion: The 755-nm picosecond alexandrite laser demonstrated moderate effectiveness and a favorable safety profile in the treatment of nevus of Ota. Pigmentary complications occurred at relatively low rates across the included studies. Further high-quality prospective and randomized controlled trials are required to confirm long-term effectiveness and safety.

Background: A distinctive and difficult phenotype, head and neck atopic dermatitis (AD) is linked to a higher disease burden and inconsistent treatment response. The effectiveness of targeted systemic therapy in this field is currently little understood. Objectives: To evaluate both the safety and effectiveness of targeted systemic therapies for individuals’ AD affecting the head and neck, such as tralokinumab, dupilumab, and upadacitinib. Methods: A meta‐analysis and systematic review were conducted using PRISMA guidelines. In three databases (PubMed, Web of Science, and EMBASE), we searched for relevant research. The qualifying research included observational studies and randomized controlled trials that reported outcomes among patients with head and neck involvement. The primary findings included the head and neck Eczema Area and Severity Index (H&N EASI‐75) and the percentage change in EASI. The Numerical Rating Scale for pruritus, the Dermatology Life Quality Index for quality of life, and safety outcomes were secondary results. The meta‐analysis was conducted using a random‐effects model. Results: Twelve studies were included. The pooled H&N EASI‐75 response rate was 51% (95% CI: 40–62), with a mean percentage reduction in EASI of −72.86% (95% CI: −78.98 to −66.74). Significant improvements were observed in pruritus (mean change −4.38) and quality of life (−9.97). Across indirect, between‐study subgroup comparisons, studies of upadacitinib showed numerically greater effect estimates than studies of dupilumab or tralokinumab; in the absence of head‐to‐head trials, these comparisons are hypothesis‐generating rather than definitive. The overall prevalence of adverse events was 48%, with conjunctivitis (7%) and herpes zoster (2%) reported. Substantial heterogeneity was noted. Conclusions: Targeted systemic therapies were associated with clinically meaningful improvements in head and neck AD, although substantial heterogeneity and the indirect nature of the drug‐specific comparisons warrant cautious interpretation. Differences in efficacy and safety profiles across agents highlight the importance of individualized treatment selection, and further head‐to‐head comparative studies are warranted.

Background and Clinical Significance: Papillon–Lefèvre syndrome (PLS) is an autosomal recessive genetic skin disorder. Genetic studies have demonstrated that mutations in the Cathepsin-C (CTSC) gene, mapped to chromosome 11q14.1–q14.3, are responsible for the pathogenesis of PLS. The hallmark characteristics of this syndrome are palmoplantar keratoderma and severe periodontal disease that leads to premature tooth loss. Palmoplantar keratoderma commonly manifests during early childhood (ages one to four), followed by the onset of severe periodontitis around the age of three to four years. Although periodontitis and premature tooth loss are considered hallmark features, a limited number of cases lacking oral involvement have been reported, underscoring the phenotypic variability in PLS. Case Presentation: This report describes a 6-year-old female patient whose chief presenting complaint was palmoplantar keratoderma, recurrent skin infections, necrotizing granulomatous inflammation of the kidney, and delayed growth; she was genetically confirmed to have a CTSC mutation associated with PLS, yet without any dental manifestations. The lack of oral manifestations and the presence of necrotizing granulomatous inflammation of the kidney in this genetically validated case highlight an atypical presentation. Conclusions: This report discusses an unusual case of PLS of a patient displaying classic skin features without any dental issues.

Psoriasis, a chronic inflammatory skin disease, is connected to psoriatic arthritis, a chronic inflammatory arthritis. Recent studies have also linked psoriasis and psoriatic arthritis to various renal disorders. This research aims to determine the prevalence and association of renal disorders in adult patients with psoriasis and compare those findings with adult patients with psoriatic arthritis. This retrospective cross-sectional study included 485 participants with psoriasis. The study evaluated demographics, psoriasis type, the presence of psoriatic arthritis, and related comorbidities, excluding individuals under the age of 18 or those with no verified diagnosis. Medical records were reviewed for renal problems, and a multivariate logistic regression was used to investigate the relationship between psoriasis and psoriatic arthritis. Overall, 10.1% of individuals with psoriasis had psoriatic arthritis. The mean age at diagnosis was 41.59±15.58 years, with 54.2% being female. Plaque psoriasis was identified in 87.2% of patients, with 46% classified as obese (body mass index [BMI]≥30). Chronic renal failure was seen in 6.2% of psoriasis patients and 6.1% of psoriatic arthritis patients. In our study, chronic renal failure rates were similar in psoriasis and psoriatic arthritis. Psoriatic arthritis was associated with an increased risk of acute kidney damage, transplantation, and dialysis.

Psoriasis, a chronic inflammatory skin disease, is connected to psoriatic arthritis, a chronic inflammatory arthritis. Recent studies have also linked psoriasis and psoriatic arthritis to various renal disorders. This research aims to determine the prevalence and association of renal disorders in adult patients with psoriasis and compare those findings with adult patients with psoriatic arthritis. This retrospective cross-sectional study included 485 participants with psoriasis. The study evaluated demographics, psoriasis type, the presence of psoriatic arthritis, and related comorbidities, excluding individuals under the age of 18 or those with no verified diagnosis. Medical records were reviewed for renal problems, and a multivariate logistic regression was used to investigate the relationship between psoriasis and psoriatic arthritis. Overall, 10.1% of psoriatic individuals had psoriatic arthritis. The mean age at diagnosis was 41.59±15.58 years, with 54.2% female. Plaque psoriasis was identified in 87.2% of patients, with 46% classified as obese (BMI≥30). Chronic renal failure was seen in 6.2% of psoriasis patients, and 6.1% of psoriatic arthritis patients. In our study, chronic renal failure rates were similar in psoriasis and psoriatic arthritis. Psoriatic arthritis was associated with an increased risk of acute kidney damage, transplantation, and dialysis.

Pachydermodactyly (PDD) is a rare, underdiagnosed benign condition characterized by asymmetrical, bilateral fusiform swellings of the hands’ proximal interphalangeal (PIP) joints. In this type of digital fibromatosis, cutaneous thickening is thought to occur due to repetitive mechanical irritation. Furthermore, due to its striking clinical appearance, PDD is commonly overlooked or misdiagnosed as other inflammatory arthropathies or pachydermoperiostosis. In addition, because of its elusive nature and resemblance to more serious conditions, clinicians should be aware of this condition. Herein, we present a case of PDD and discuss the differential diagnoses to improve recognition and prevent misdiagnosis.